<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title>Frontiers in Endocrinology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Endocrinol.</abbrev-journal-title>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fendo.2025.1500630</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Activation of the Nrf2/HO-1 pathway restores N-acetylcysteine-induced impairment of the hypothalamus-pituitary-adrenal axis negative feedback by up-regulating GR&#x3b1; expression and down-regulating GR&#x3b2; expression into pituitary glands</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chaves</surname>
<given-names>Amanda Silva</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/808743"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ventura</surname>
<given-names>Ra&#xed;ssa Duarte</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2949408"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pacini</surname>
<given-names>Maria Florencia</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2918114"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Magalh&#xe3;es</surname>
<given-names>Nathalia Santos</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1178917"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silva</surname>
<given-names>Patr&#xed;cia Machado Rodrigues e</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/47912"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martins</surname>
<given-names>Marco Aur&#xe9;lio</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/35654"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>P&#xe9;rez</surname>
<given-names>Ana Rosa</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/227637"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Carvalho</surname>
<given-names>Vinicius Frias</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/451481"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Laboratory of Inflammation, Center for Research, Innovation, and Surveillance in Covid-19 and Health Emergencies, Oswaldo Cruz Institute, Oswaldo Cruz Foundation</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Institute of Clinical and Experimental Immunology (IDICER-CONICET UNR)</institution>, <addr-line>Rosario</addr-line>, <country>Argentina</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Oswaldo Cruz Institute, Oswaldo Cruz Foundation</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Rio de Janeiro Research Network on Neuroinflammation (RENEURIN), Oswaldo Cruz Institute, Oswaldo Cruz Foundation</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>INOVA-IOC Network on Neuroimmunomodulation, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Ashu Johri, Independent Researcher, New York, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Viridiana Alcantara-Alonso, Imperial College London, United Kingdom</p>
<p>Waldemar Kanczkowski, Technical University Dresden, Germany</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Vinicius Frias Carvalho, <email xlink:href="mailto:viniciusfrias@hotmail.com">viniciusfrias@hotmail.com</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>01</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1500630</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>09</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>01</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Chaves, Ventura, Pacini, Magalh&#xe3;es, Silva, Martins, P&#xe9;rez and Carvalho</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Chaves, Ventura, Pacini, Magalh&#xe3;es, Silva, Martins, P&#xe9;rez and Carvalho</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>We previously showed that antioxidants induced an impairment of negative feedback of the hypothalamus-pituitary-adrenal (HPA) axis in rats, in parallel to a down-regulation of the glucocorticoid receptor (GR) and nuclear factor erythroid 2-related factor 2 (Nrf2) expression in the pituitary gland. This study evaluated the role of the Nrf2-heme-oxygenase-1 (HO-1) pathway on the impairment of the negative feedback of the HPA axis induced by N-acetylcysteine (NAC). Male Swiss-Webster mice were orally supplemented with NAC for 5 consecutive days. The Nrf2-HO-1 pathway activator cobalt protoporphyrin IX (CoPPIX) was injected intraperitoneally on days 2 and 5 after the starting of NAC supplementation. NAC reduced the expression of Nrf2 in the pituitary of mice. Furthermore, NAC induced adrenal enlargement and hypercorticoidism, along with a decrease in the GR&#x3b1; expression and an increase of GR&#x3b2; expression in the pituitary gland. Treatment with CoPPIX reduced adrenal enlargement, systemic corticosterone levels, and GR&#x3b2; expression in the pituitary gland of mice supplemented with NAC, besides increasing the expression of GR&#x3b1;. CoPPIX treatment also restored the failure in the negative feedback of the HPA axis induced by NAC. In conclusion, these findings showed that NAC reduced the Nrf2-HO-1 pathway activation in the pituitary gland, in a mechanism probably related to a local downregulation of GR&#x3b1; and an up-regulation of GR&#x3b2;, leading to a failure of negative feedback of the HPA axis and consequently to the hyperactivity of this neuroendocrine axis.</p>
</abstract>
<kwd-group>
<kwd>antioxidants</kwd>
<kwd>glucocorticoid</kwd>
<kwd>GR isoforms</kwd>
<kwd>HPA axis</kwd>
<kwd>Nrf-2</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="45"/>
<page-count count="10"/>
<word-count count="4033"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Neuroendocrine Science</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>The hypothalamus-pituitary-adrenal (HPA) axis is a neuroendocrine system regulated by the circadian cycle and stress (<xref ref-type="bibr" rid="B1">1</xref>). Under normal conditions, glucocorticoids, the final product of the HPA axis, are produced through the activation of the adrenocorticotropic hormone (ACTH)-melanocortin receptor 2 (MC2R) signaling pathway in the adrenal glands (<xref ref-type="bibr" rid="B2">2</xref>). Chronic activation of the HPA axis can have damaging effects on immune, cardiovascular, metabolic, and neural functions, increasing the risk of immune system dysfunction, mood disorders, and metabolic and cardiovascular diseases (<xref ref-type="bibr" rid="B3">3</xref>). To prevent these deleterious effects of chronic hypercortisolism, the HPA axis function is controlled by a glucocorticoid-dependent negative feedback system that is essential for ending the stress response. In corticotroph cells, the activation of glucocorticoid receptor (GR)-&#x3b1; isoform by glucocorticoids is crucial for the negative feedback of the HPA axis (<xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>Reactive oxygen species (ROS), such as superoxide, hydroxyl radicals, and hydrogen peroxide, are produced by oxygen reduction (<xref ref-type="bibr" rid="B5">5</xref>). As the overproduction of ROS is toxic to cells, its synthesis is finely controlled by endogenous antioxidant enzymes (<xref ref-type="bibr" rid="B6">6</xref>). ROS are known to act as signaling molecules in physiological processes, activating a defensive response, including nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase (HO)-1 pathway, which appears to protect the organism from subsequent higher stresses (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). Furthermore, the loss of Nrf2 activity in mouse fibroblasts, hepatocytes, and liver cells disrupts local circadian rhythms (<xref ref-type="bibr" rid="B10">10</xref>). Although the disruption of local circadian rhythms can increase pituitary gland activation (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>), the effect of Nrf2 on the negative feedback of the HPA axis is unclear.</p>
<p>In previous works, we demonstrated that oral supplementation with antioxidants induces hyperactivity of the HPA axis in mice and rats (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). The antioxidant-induced hyperactivation of this axis was related to overexpression of MC2R and steroidogenic machinery in the adrenal gland, along with a down-regulation of GR in the pituitary gland, leading to a failure of the negative feedback mechanism of the HPA axis. We also showed that N-acetylcysteine (NAC) reduced the expression of Nrf2 and HO-1 in the pituitary gland of rats (<xref ref-type="bibr" rid="B13">13</xref>). In this study, we evaluated the effect of Nrf2/HO-1 pathway activator cobalt protoporphyrin IX (CoPPIX) (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>) on the NAC-induced hypercortisolism in healthy mice.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s3_1">
<label>2.1</label>
<title>Animals</title>
<p>Following the guidelines of the Committee on Use of Laboratory Animals of Oswaldo Cruz Institute (CEUA-IOC/Fiocruz, license L-027/2016 and L-004/2024), male Swiss-Webster mice obtained from Science and Technology in Biomodels Institute of Fiocruz were used. Mice aged between 4 and 6 weeks were housed in groups of five in temperature-, humidity-, and light-controlled (12 h light: 12 h darkness cycle) colony room. Mice were given access <italic>ad libitum</italic> to food and water.</p>
</sec>
<sec id="s3_2">
<label>2.2</label>
<title>Antioxidant supplementation and treatment</title>
<p>The mice were supplemented with antioxidant N-acetyl cysteine (NAC) (150 mg/kg body weight) (Sigma Chemical Co., Saint Louis, MO, USA) (<xref ref-type="bibr" rid="B17">17</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>) by gavage once a day, during five consecutive days. Control mice received an equal volume of vehicles (sterile saline 0.9%). The mice were treated concomitantly with Co (III) Protoporphyrin IX chloride (Nrf2-HO-1 pathway activator &#x2013; CoPPIX) (10 mg/kg body weight, i.p.) (Co654-9, Frontier Scientific, Inc., Logan, UT, USA) (<xref ref-type="bibr" rid="B14">14</xref>) on days 2 and 5 after the start of NAC supplementation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). CoPPIX was diluted with NaOH 0.1N (10% final volume) (Merck, Rio de Janeiro, Brazil), and then, HCl 1N (Merck) to obtain a solution with pH 7.4. Untreated mice received an equal volume of vehicles. To analyze corticoid-induced negative feedback sensitivity, a group of animals received dexamethasone (20 &#xb5;g/kg body weight, s.c.) (Sigma Chemical Co.) 1h before the euthanasia. Control mice were treated s.c. with sterile saline 0.9%. All analyses were performed 24 hours after the last supplementation with NAC. All solutions were freshly prepared immediately before use. To analyze whether the effect of NAC is sustainable after the interruption of the supplementation, we administered NAC by gavage once a day, during five consecutive days, and analyzed plasma corticosterone levels 24h and 15 days after the last supplementation with NAC.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>CoPPIX increases the under-expression of Nrf2 and HO-1 in the pituitary glands of mice supplemented with NAC. <bold>(A)</bold> <italic>In vivo</italic> protocol. Mice were supplemented with NAC (150 mg/Kg, gavage) daily for 5 consecutive days and treated with CoPPIX (10 mg/Kg, i.p.) on days 2 and 5 after the starting of oral supplementation with the antioxidant. Non-supplemented animals received an equal amount of vehicles (NaOH 0.1N and HCl 1N, pH = 7.4, i.p.), and analyses were performed 24 h after the last supplementation with NAC and/or treatment with CoPPIX. <bold>(B, C)</bold> Nrf2 gene expression in adrenal and pituitary glands of mice, measured by qPCR, respectively. Data are expressed as the mean &#xb1; SEM. *P &lt; 0.05. CoPPIX, Cobalt protoporphyrin IX; HO-1, Heme-oxygenase-1; NAC, N-acetylcysteine; Nrf2, Nuclear factor erythroid 2-related factor 2.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fendo-16-1500630-g001.tif"/>
</fig>
</sec>
<sec id="s3_3">
<label>2.3</label>
<title>Evaluation of mRNA expression of GR&#x3b1;, GR&#x3b2;, and Nfr-2 by real time PCR</title>
<p>Total RNA was isolated from adrenal and pituitary glands using TRI Reagent<sup>&#xae;</sup> and followed reverse-transcribed to cDNA using the RevertAid Reverse Transcriptase (Thermo Fisher Scientific, Waltham, USA). Real-time PCR was performed with the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, USA) using a Mix (5x HOT FIREPol<sup>&#xae;</sup> EvaGreen<sup>&#xae;</sup> qPCR Mix Plus with ROX; Solis BioDyne, Estonia) according to the manufacturer&#x2019;s instructions. The amplification program included an initial activation step at 95&#xb0;C for 15min, followed by denaturation at 95&#xb0;C for 15s, annealing between 59&#xb0;-62&#xb0;C and finally elongation at 72&#xb0;C for 20s, for 40 cycles. Fluorescence was measured after each extension step, and the specificity of amplification was evaluated by melting curve analysis. The housekeeping gene GADPH was used as a control to normalize RNA samples. Relative gene expression levels were calculated using the &#x394;&#x394;C<sub>T</sub> method (<xref ref-type="bibr" rid="B20">20</xref>). Amplification efficiencies were identical or similar between genes of interest and controls. Primers were designed in our laboratory and purchased from Eurofins Genomics Scientific, Inc. (Louisville, USA) or Invitrogen Thermo Fisher Scientific, Inc. (Carlsbad, USA). The primer used were: i) GAPDH - forward: AGCAATGCATCCTGCACCACCA; reverse: ATGCCAGTGAGCTTCCCGTTCA; ii) GR&#x3b1; - forward: AAAGAGCTAGGAAAAGCCATTGTC; reverse: TCAGCTAACATCTCTGGGAATTCA; iii) GR&#x3b2; - forward: AAAGAGCTAGGAAAAGCCATTGTC; reverse: CTGTCTTTGGGCTTTTGAGATAGG; iv) Nrf2 - forward: TAGATGACCATGAGTCGCTTG; reverse: GCCAAACTTGCTCCATGTCC.</p>
</sec>
<sec id="s3_4">
<label>2.4</label>
<title>Western blot analysis</title>
<p>The pituitary glands were homogenized in RIPA buffer containing protease and phosphatase inhibitor cocktails, and then, the protein content was quantified by the BCA method (<xref ref-type="bibr" rid="B21">21</xref>). 60 &#x3bc;g total protein/lane was resolved on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, for evaluation of GR protein expression, and afterward electrotransferred through a semi-dry transfer apparatus (Trans-Blot SD; Bio-Rad, Hercules, CA, USA) to a nitrocellulose membrane. Subsequently, the membrane was blocked with a solution containing Tris-buffered saline, 5% bovine serum albumin, and 0.1% Tween 20, pH 7.4 (TBST), for 90 minutes at room temperature. Then, the membrane was incubated with a primary antibody dissolved in the blocking solution overnight at 4&#xb0;C. Primary antibody against anti-GR (1:200; Santa Cruz Biotechnology) was used. The housekeeping anti-&#x3b2;-actin (1:1000; Santa Cruz Biotechnology) was used as the standard. Afterward, the membrane was incubated with an HRP conjugated secondary antibody polyclonal anti-rabbit IgG HRP (1:10.000, Invitrogen ThermoFisher Scientific, MA, USA), or monoclonal anti-mouse IgGs HRP (1:1000, R&amp;D System, Minneapolis, MN, USA) for 60 minutes at room temperature, and the immunocomplexes were visualized by using a ChemiDoc MP Imaging System 6.0.1 (Bio-Rad Laboratories, Inc, Hercules, CA, USA). Then, the band density measurements were analyzed by Image Lab software version 6.1.0 (Bio-Rad Laboratories, Inc). The description of all the antibodies used is in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref>.</p>
</sec>
<sec id="s3_5">
<label>2.5</label>
<title>Hormone quantification</title>
<p>After euthanasia (ketamine 140 mg/Kg and xylazine 20 mg/Kg i.p.) of mice, during nadir (08:00h) of the circadian rhythm (<xref ref-type="bibr" rid="B21">21</xref>). Blood was immediately collected from the abdominal aorta with heparinized (40 U/ml) saline, centrifuged for 20 min at 1000 x g, and stored at -20&#xb0;C until use. The ELISA kit detected plasma corticosterone levels following the manufacturer&#x2019;s guidelines (Cayman Chemical, 501320, Cedarlane Labs, Canada).</p>
</sec>
<sec id="s3_6">
<label>2.6</label>
<title>Statistical analysis</title>
<p>The data are reported as the mean &#xb1; standard error of the mean (SEM). Data distribution was assessed by Kolmogorov-Smirnov. Data with normal distribution was statistically analyzed by one-way ANOVA followed by Tukey&#x2019;s multiple comparison <italic>post-hoc</italic> test. Data without normal distribution was evaluated by Kruskall-Wallis followed by the U-Mann Whitney test. All statistical analysis was performed with GraphPad Prism 8 software. Probability values (p) of 0.05 or less were considered significant. Determining if the frequency distribution of a given data set follows a normal distribution or not is among the first steps of data analysis.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s4_1">
<label>3.1</label>
<title>CoPPIX restores NAC-induced under-expression of Nrf-2 in the pituitary gland of mice</title>
<p>Supplementation with NAC (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) did not alter the mRNA expression of Nrf2 in adrenal glands compared to non-supplemented mice (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1B</bold>
</xref>); however, it reduced the mRNA expression of Nrf2 in the pituitary glands (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1C</bold>
</xref>).</p>
</sec>
<sec id="s4_2">
<label>3.2</label>
<title>CoPPIX reduces adrenal enlargement and hypercorticoidism induced by NAC supplementation</title>
<p>NAC supplementation did not affect the overall body weight of mice (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>), but induced adrenal enlargement, which was evidenced by an increase in the adrenal weight and the adrenal-to-body weight ratio (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2B, C</bold>
</xref>, respectively) compared to non-supplemented mice. However, the treatment with CoPPIX prevented the adrenal enlargement observed in NAC-supplemented mice without modifying the body weight (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2A-C</bold>
</xref>). CoPPIX did not alter these readouts in non-supplemented mice. In addition, NAC increased circulating corticosterone levels compared to non-supplemented mice (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>). Remarkably, this change was sensitive to CoPPIX treatment, as evidenced by conditions in which the CoPPIX did not alter this parameter in non-supplemented mice (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>CoPPIX reduces adrenal enlargement and plasma corticosterone levels observed in mice supplemented with NAC. Mice were supplemented with NAC (150 mg/Kg, gavage) daily for 5 consecutive days and treated with CoPPIX (10 mg/Kg, i.p.) on days 2 and 5 after the starting of oral supplementation with the antioxidant. Non-supplemented animals received an equal amount of vehicle (NaOH 0.1N and HCl 1N, pH = 7.4, i.p.), and analyses were performed 24 h after the last supplementation with NAC and/or treatment CoPPIX. <bold>(A)</bold> Body weight of mice. <bold>(B)</bold> Adrenal weight of mice. <bold>(C)</bold> The ratio between adrenal and body weight. <bold>(D)</bold> Plasma quantification of corticosterone levels. Data are expressed as the mean &#xb1; SEM. *P &lt; 0.05. CoPPIX, Cobalt protoporphyrin IX; NAC, N-acetylcysteine.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fendo-16-1500630-g002.tif"/>
</fig>
</sec>
<sec id="s4_3">
<label>3.3</label>
<title>CoPPIX restored NAC-induced failure in the negative feedback of the HPA axis by increasing the expression of GR&#x3b1; in the pituitary gland of mice</title>
<p>Dexamethasone reduced plasma corticosterone levels in non-supplemented mice, however; it failed to inhibit this readout in NAC-supplemented mice, indicating an impairment in the negative feedback of the HPA axis due to NAC supplementation in mice. Notably, CoPPIX restored dexamethasone&#x2019;s ability to reduce plasma corticosterone levels in NAC-supplemented mice, while it did not affect this parameter in non-supplemented mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). We also demonstrated that NAC decreased GR protein expression in the pituitary gland of mice, which was sensitive to CoPPIX treatment (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1</bold>
</xref>). Furthermore, CoPPIX did not modify this readout in non-supplemented mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>). In addition, NAC significantly reduced GR&#x3b1; expression (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>) and increased GR&#x3b2; expression in the pituitary gland of mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref>). Treatment with CoPPIX significantly increased GR&#x3b1; expression and decreased GR&#x3b2; expression in the pituitary gland of mice supplemented with NAC (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3C, D</bold>
</xref>, respectively). CoPPIX treatment did not significantly alter GR&#x3b1; and GR&#x3b2; in non-supplemented mice.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>CoPPIX restores the impairment of negative feedback of the HPA axis in mice supplemented with NAC by restoring the imbalance in the GR isoforms in the pituitary gland. Mice were supplemented with NAC (150 mg/Kg, gavage) daily for 5 consecutive days and treated with CoPPIX (10 mg/Kg, i.p.) on days 2 and 5 after the starting of oral supplementation with the antioxidant. Non-supplemented animals received an equal amount of vehicle (NaOH 0.1N and HCl 1N, pH = 7.4, i.p.), and analyses were performed 24 h after the last supplementation with NAC and/or treatment CoPPIX. Some groups of mice were injected with dexamethasone (20 &#xb5;g/Kg, s.c.) or vehicle (saline 0.9%, s.c.) 1h before de euthanasia. <bold>(A)</bold> Quantification of plasma corticosterone levels after dexamethasone suppression test <italic>in vivo</italic>. <bold>(B)</bold> Expression of total GR in pituitary glands was determined by western blot. The data were normalized to &#x3b2;-actin and represented as the ratio between the expressions of GR: &#x3b2;-actin relative to the control. <bold>(C, D)</bold> GR&#x3b1; and GR&#x3b2; gene expression in pituitary glands of mice measured by qPCR, respectively. Data are expressed as the mean &#xb1; SEM. *P &lt; 0.05. CoPPIX, Cobalt protoporphyrin IX; Dexa, Dexamethasone; GR, glucocorticoid receptor; NAC, N-acetylcysteine.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fendo-16-1500630-g003.tif"/>
</fig>
</sec>
<sec id="s4_4">
<label>3.4</label>
<title>NAC increases plasma corticosterone levels in mice even after discontinuing supplementation for 15 days</title>
<p>We observed that dietary supplementation with NAC (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>) significantly increased plasma corticosterone levels in mice 24h (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>) as well as 15 days (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>) after the last administration of the antioxidant with the same magnitude of the response (3.5-fold and 3.4-fold, respectively).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>NAC increases plasma corticosterone levels in mice even after discontinuing supplementation for 15 days. <bold>(A)</bold> <italic>In vivo</italic> protocol. Mice were supplemented with NAC (150 mg/Kg, gavage) daily for 5 consecutive days. Non-supplemented animals received an equal amount of vehicles (NaOH 0.1N and HCl 1N, pH = 7.4, i.p <bold>(B)</bold> Quantification of plasma corticosterone levels 24 h after the last supplementation with NAC. <bold>(C)</bold> Quantification of plasma corticosterone 15 days after the last NAC supplementation. Data are expressed as the mean &#xb1; SEM. *P &lt; 0.05. NAC, N-acetylcysteine.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fendo-16-1500630-g004.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>This study investigated the effect of Nrf2/HO-1 pathway activator CoPPIX on NAC-induced impairment of HPA axis negative feedback in healthy mice. We found that CoPPIX treatment increased the expression of Nrf2 in the pituitary gland of NAC-supplemented mice. In addition, CoPPIX treatment inhibited NAC-induced hypercorticoidism in healthy mice, parallel to a reduction in adrenal enlargement. The decrease in the corticosterone production in the adrenal glands of NAC-supplemented mice treated with CoPPIX was correlated with an improvement in the negative feedback of the HPA axis, as well as up-regulation of GR&#x3b1; and downregulation of GR&#x3b2; expression in the pituitary gland. Our findings suggest that the impairment of the negative feedback of the HPA axis induced by NAC supplementation is probably due to an imbalance in GR isoform expression in the pituitary gland, caused by local downregulation of the Nrf2-HO-1 pathway.</p>
<p>Currently, many people incorporate antioxidants into their daily regimen as a proactive measure to combat the effects of aging, including the development of age-related diseases (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). Nevertheless, numerous clinical trials evaluating the efficacy and safety of antioxidant supplementation have failed to show beneficial readouts and, in some cases, have suggested an increase in overall mortality rates (<xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B26">26</xref>). Previously, we showed that supplementation with two different antioxidants, NAC and vitamin E, increased plasma corticosterone levels in mice and rats (<xref ref-type="bibr" rid="B13">13</xref>). Additionally, NAC was shown to abolish the ability of exogenous glucocorticoids to perform negative feedback on the HPA axis in rats, alongside a decrease in the expression of GR, Nrf2, and HO-1 in the pituitary gland (<xref ref-type="bibr" rid="B13">13</xref>). However, the causal effect of the downregulation of the Nrf2-HO-1 pathway on NAC-induced impairment of the HPA axis negative feedback remains unknown. Therefore, we hypothesized that activating the Nrf2-HO-1 pathway by CoPPIX in the pituitary of NAC-supplemented mice could improve the HPA axis negative feedback failure observed in these animals.</p>
<p>Initially, we confirmed our previous findings in rats and demonstrated that NAC supplementation also reduced the expression of Nrf2 in the pituitary gland of healthy mice, even with a shorter supplementation period. Our data agree with the literature that showed that treatment with NAC reduced the expression of Nrf2 and HO-1 in non-stimulated human umbilical vein cells (HUVECs) and C2C12 myotube cells and AuNP-induced up-regulation of Nrf2-HO-1 pathway in human vascular endothelial cells (<xref ref-type="bibr" rid="B27">27</xref>&#x2013;<xref ref-type="bibr" rid="B29">29</xref>).</p>
<p>To evaluate whether activation of the Nrf2-HO-1 pathway in the pituitary of NAC-supplemented mice could improve the negative feedback of the HPA axis, we first evaluated if CoPPIX treatment could reduce the hypercorticoidism observed in these animals. First, we confirmed that supplementation with NAC increased the plasma corticosterone levels in mice. Although antioxidant treatment decreases corticosterone levels in several models of diseases, including brain oxidative stress induced by lipopolysaccharide and streptozotocin-induced diabetes in rats (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>), we showed that physiological ROS act as messenger molecules in pituitary cells of healthy mice and are vital to their homeostasis maintenance. Furthermore, we showed that CoPPIX treatment inhibited both NAC-induced adrenal enlargement and hypercorticoidism in mice. These findings suggest that reduced activation of the Nrf2-HO-1 signaling pathway in the pituitary is involved in the hyperactivity of the HPA axis induced by NAC supplementation. While we believe that CoPPIX does not act directly on the adrenal glands &#x2013; since NAC supplementation did not alter Nrf2 mRNA expression in the adrenals &#x2013; we cannot entirely rule out the possibility that CoPPIX restored NAC-induced a reduction in the MC2R expression in the adrenal gland and, consequently, the adrenal insensitivity to ACTH stimulation. In fact, the downregulation of HO-1 expression in adrenocortical cells has been shown to increase ACTH-induced progesterone steroidogenesis <italic>in vitro</italic> (<xref ref-type="bibr" rid="B32">32</xref>), indicating that the Nrf2-HO-1 pathway plays a crucial role in adrenal steroidogenesis.</p>
<p>Since CoPPIX inhibited NAC-induced hypercorticoidism and restored the expression of Nrf2 and HO-1 in the pituitary gland of mice, we further evaluated the effect of Nrf2-HO-1pathway activation on the functioning of the negative feedback of the HPA axis. For this, we assessed the sensitivity of the HPA axis to negative feedback induced by the synthetic exogenous glucocorticoid dexamethasone in NAC-supplemented mice treated or not with CoPPIX. Dexamethasone reduced circulating corticosterone levels in non-supplemented mice, but did not affect plasma glucocorticoid levels in NAC-supplemented mice, indicating that NAC impairs the negative feedback of the HPA axis. Interestingly, CoPPIX treatment significantly reduced plasma corticosterone levels in dexamethasone-treated and NAC-supplemented mice, indicating that CoPPIX restored the ability of glucocorticoids to perform negative feedback on the HPA axis.</p>
<p>It is well known that the inhibition of stressor-evoked HPA axis responses at the pituitary level is mediated by the activation of GR (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). Furthermore, NAC reduces the expression of GR in the hypothalamus of mice on a high-cholesterol diet (<xref ref-type="bibr" rid="B35">35</xref>) and in the pituitary of healthy rats (<xref ref-type="bibr" rid="B13">13</xref>). As expected, we showed that NAC significantly reduced GR protein expression in healthy mice&#x2019;s pituitary. Treatment with CoPPIX significantly increased the density of GR in this gland of mice supplemented with NAC, strongly confirming that the downregulation of the Nrf2-HO-1 pathway has a causal relationship with the failure of the negative feedback of the HPA axis observed in mice supplemented with NAC. Among the isoforms of GR produced by alternative splicing GR&#x3b1; and GR&#x3b2; stand out. Unlike GR&#x3b1;, which is the classic receptor responsible for glucocorticoid actions, GR&#x3b2; cannot bind to glucocorticoids. Nevertheless, GR&#x3b2; forms a heterodimer with GR&#x3b1; and exerts a dominant-negative effect on GR&#x3b1;-mediated transcription (<xref ref-type="bibr" rid="B36">36</xref>&#x2013;<xref ref-type="bibr" rid="B38">38</xref>). Although Otto et&#xa0;al. described that GR&#x3b2; is not conserved across species and its physiological significance in humans appears questionable, they only evaluated the exons 7, 8, and 9 of the GR loci (<xref ref-type="bibr" rid="B39">39</xref>). Currently, it is well known that the mGR&#x3b2; isoform arises from a distinct alternative splicing mechanism utilizing intron 8, rather than exon 9 as in humans, and that this isoform showed the same properties reported for human GR&#x3b2; (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). Interestingly, dietary supplementation with NAC significantly reduced the expression of GR&#x3b1; mRNA and increased the expression of GR&#x3b2; mRNA in the pituitary gland of healthy mice. This data can explain the exact mechanism by which supplementation with NAC completely impairs the HPA axis&#x2019; negative feedback, even with a slight but significant reduction in the expression of total GR protein levels. Treatment with CoPPIX increased the expression of GR&#x3b1; mRNA in the pituitary gland of NAC-supplemented mice, however, strongly decreased the expression of GR&#x3b2; mRNA. Our data showed that the activation of the Nrf2-HO-1 pathway restores the negative feedback of the HPA axis of mice supplemented with NAC by upregulating the expression of the receptor responsible for the glucocorticoid actions, together with a downregulation of the expression of the receptor responsible by the impairment of GR&#x3b1;-mediated activities. In addition, for the first time, we showed that the Nrf2-HO-1 pathway can regulate direct or indirectly the expression of GR isoforms, therefore, our findings contribute novel insights into GR potential regulatory mechanism. Nevertheless, further studies will be required to delineate the exact intracellular pathways involved with the Nrf2/HO-1 pathway-induced glucocorticoid receptor gene expression modulation. Although we strongly believe that activation of the Nrf2-HO-1 pathway in mice supplemented with NAC restores HPA axis negative feedback by modulating the expression of GR isoforms in the mouse pituitary, it is imperative to emphasize that an important limitation of the work is the lack of circulating ACTH levels measurement. We can mainly rule out that NAC supplementation might reduce corticosterone metabolism in the liver and intestine (<xref ref-type="bibr" rid="B42">42</xref>), and that CoPPIX treatment might be preventing this possible extra HPA axis effect of NAC supplementation.</p>
<p>We also evaluated the effect of the discontinuation of the supplementation of NAC on the plasma corticosterone levels of mice to evaluate whether NAC-induced downregulation of the HPA axis negative feedback is part of an adaptation period or if this can have a long-lasting effect on the HPA axis stress response. We showed that even after we stopped the dietary supplementation of mice with NAC for 15 days, they showed the same magnitude of increase in circulating corticosterone levels when compared to mice who did not have their supplementation interrupted. Therefore, we can hypothesize that the supplementation of NAC in mice for only 5 days induces a sustainable alteration of the control of glucocorticoid production for at least 15 days. One limitation of our study was that we used only male mice to investigate the effect of NAC on the hyperactivity of the HPA axis in healthy animals, and the effects of NAC on HPA axis function in females should also be considered.</p>
<p>The CoPPIX enhances cellular antioxidant defenses and reduces the production of ROS by inducing the HO-1 signaling pathway, protecting cells from oxidative damage (<xref ref-type="bibr" rid="B43">43</xref>). Despite the promising preclinical data, the clinical development of CoPPIX as an antioxidant therapy is in its early stages. Further detailed preclinical and clinical studies are necessary to fully understand the therapeutic potential and safety use of CoPPIX in humans. Moreover, the exploration of CoPPIX and other Nrf2-HO-1 activators holds the potential for developing novel therapeutic strategies for oxidative stress-related diseases (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>).</p>
<p>In summary, our results indicate that NAC-induced hyperactivity of the HPA axis in mice is related to the reduction of the activity of the Nrf2-HO-1 pathway in the pituitary gland. This effect seems to be caused by a reduced GR&#x3b1; mRNA and an increased GR&#x3b2; mRNA transcription, which could lead to a subsequent impairment of the negative feedback of the HPA axis. In addition, the activation of the Nrf2-HO-1 pathway with CoPPIX normalizes the dysregulation in the pituitary gland induced by NAC supplementation and, consequently, stabilizes the negative feedback of the HPA axis after dexamethasone suppression test.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Material</bold></xref>. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The animal study was reviewed and approved by committee on Use of Laboratory Animals of the Oswaldo Cruz Institute (CEUA-IOC/FIOCRUZ, license L-027/2016 and L-004/2024). The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>AC: Conceptualization, Formal analysis, Methodology, Writing &#x2013; original draft. RV: Formal analysis, Methodology, Writing &#x2013; review &amp; editing. MP: Formal analysis, Methodology, Writing &#x2013; review &amp;&#xa0;editing. NM: Formal analysis, Methodology, Writing &#x2013; review &amp; editing. PS: Formal analysis, Funding acquisition, Resources, Writing &#x2013; review &amp; editing. MM: Formal analysis, Funding acquisition, Resources, Writing &#x2013; review &amp; editing. AP: Formal analysis, Resources, Writing &#x2013; review &amp; editing. VC: Conceptualization, Formal analysis, Funding acquisition, Project administration, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was financial supported by Funda&#xe7;&#xe3;o Carlos Chagas de Amparo &#xe0; Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento Cient&#x131;&#x301;fico e Tecnolo&#x301;gico (CNPq), Programa de Aux&#x131;&#x301;lio &#xe0; Pesquisa (PAPESVI/FIOCRUZ), Programa INOVA FIOCRUZ, and Ministe&#x301;rio da Sau&#x301;de, Brazil. The funding agencies had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fendo.2025.1500630/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fendo.2025.1500630/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<fn-group>
<title>Abbreviations</title>
<fn fn-type="abbr" id="abbrev1">
<p>ACTH, adrenocorticotrophic hormone; CoPPIX, cobalt protoporphyrin IX; GR, glucocorticoid receptor; HCL, hydrogen chloride; HO-1, heme oxygenase-1; HPA, hypothalamus-pituitary-adrenal axis; MC2R, melanocortin-2 receptor; NAC, N-acetylcysteine; NAOH, sodium hydroxide; Nfr2, nuclear factor erythroid 2-related factor 2; qPCR, polymerase chain reaction; ROS, reactive oxygen species.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russell</surname> <given-names>G</given-names>
</name>
<name>
<surname>Lightman</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The human stress response</article-title>. <source>Nat Rev Endocrinol</source>. (<year>2019</year>) <volume>15</volume>:<page-range>525&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41574-019-0228-0</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dores</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Londraville</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Prokop</surname> <given-names>J</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>P</given-names>
</name>
<name>
<surname>Dewey</surname> <given-names>N</given-names>
</name>
<name>
<surname>Lesinski</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>MOLECULAR EVOLUTION OF GPCRS: melanocortin/melanocortin receptors</article-title>. <source>J Mol Endocrinol</source>. (<year>2014</year>) <volume>52</volume>:<page-range>T29&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1530/JME-14-0050</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheng</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Bales</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Myers</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Bautista</surname> <given-names>AI</given-names>
</name>
<name>
<surname>Roueinfar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hale</surname> <given-names>TM</given-names>
</name>
<etal/>
</person-group>. <article-title>The hypothalamic-pituitary-adrenal axis: development, programming actions of hormones, and maternal-fetal interactions</article-title>. <source>Front Behav Neurosci</source>. (<year>2021</year>) <volume>14</volume>:<elocation-id>601939</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fnbeh.2020.601939</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harno</surname> <given-names>E</given-names>
</name>
<name>
<surname>Gali Ramamoorthy</surname> <given-names>T</given-names>
</name>
<name>
<surname>Coll</surname> <given-names>AP</given-names>
</name>
<name>
<surname>White</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>POMC: the physiological power of hormone processing</article-title>. <source>Physiol Rev</source>. (<year>2018</year>) <volume>98</volume>:<page-range>2381&#x2013;430</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/physrev.00024.2017</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forman</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Augusto</surname> <given-names>O</given-names>
</name>
<name>
<surname>Brigelius-Flohe</surname> <given-names>R</given-names>
</name>
<name>
<surname>Dennery</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Kalyanaraman</surname> <given-names>B</given-names>
</name>
<name>
<surname>Ischiropoulos</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Even free radicals should follow some rules: A Guide to free radical research terminology and methodology</article-title>. <source>Free Radic Biol Med</source>. (<year>2015</year>) <volume>78</volume>:<page-range>233&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.10.504</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Miao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Reactive oxygen species and nrf2: functional and transcriptional regulators of hematopoiesis</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2019</year>) <volume>2019</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/5153268</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdelnaser</surname> <given-names>M</given-names>
</name>
<name>
<surname>Alaaeldin</surname> <given-names>R</given-names>
</name>
<name>
<surname>Attya</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Fathy</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Modulating Nrf-2/HO-1, apoptosis and oxidative stress signaling pathways by gabapentin ameliorates sepsis-induced acute kidney injury</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source>. (<year>2024</year>) <volume>397</volume>:<page-range>947&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00210-023-02650-y</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname> <given-names>S</given-names>
</name>
<name>
<surname>Buttari</surname> <given-names>B</given-names>
</name>
<name>
<surname>Panieri</surname> <given-names>E</given-names>
</name>
<name>
<surname>Profumo</surname> <given-names>E</given-names>
</name>
<name>
<surname>Saso</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>An overview of nrf2 signaling pathway and its role in inflammation</article-title>. <source>Molecules</source>. (<year>2020</year>) <volume>25</volume>:<elocation-id>5474</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/molecules25225474</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gough</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Cotter</surname> <given-names>TG</given-names>
</name>
</person-group>. <article-title>Hydrogen peroxide: a Jekyll and Hyde signalling molecule</article-title>. <source>Cell Death Dis</source>. (<year>2011</year>) <volume>2</volume>:<page-range>e213&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cddis.2011.96</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wible</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Ramanathan</surname> <given-names>C</given-names>
</name>
<name>
<surname>Sutter</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Olesen</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Kensler</surname> <given-names>TW</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>AC</given-names>
</name>
<etal/>
</person-group>. <article-title>NRF2 regulates core and stabilizing circadian clock loops, coupling redox and timekeeping in Mus musculus</article-title>. <source>Elife</source>. (<year>2018</year>) <volume>7</volume>:<fpage>153</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.7554/eLife.31656</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Heaney</surname> <given-names>AP</given-names>
</name>
</person-group>. <article-title>Nuclear receptors as regulators of pituitary corticotroph pro-opiomelanocortin transcription</article-title>. <source>Cells</source>. (<year>2020</year>) <volume>9</volume>:<elocation-id>900</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells9040900</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsukamoto-Yamauchi</surname> <given-names>N</given-names>
</name>
<name>
<surname>Terasaka</surname> <given-names>T</given-names>
</name>
<name>
<surname>Iwasaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Otsuka</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Interaction of pituitary hormones and expression of clock genes modulated by bone morphogenetic protein-4 and melatonin</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2015</year>) <volume>459</volume>:<page-range>172&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2015.02.100</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prevatto</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Torres</surname> <given-names>RC</given-names>
</name>
<name>
<surname>Diaz</surname> <given-names>BL</given-names>
</name>
<name>
<surname>e Silva</surname> <given-names>PMR</given-names>
</name>
<name>
<surname>Martins</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>VF</given-names>
</name>
</person-group>. <article-title>Antioxidant treatment induces hyperactivation of the HPA axis by upregulating ACTH receptor in the adrenal and downregulating glucocorticoid receptors in the pituitary</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2017</year>) <volume>2017</volume>:<fpage>159</fpage>&#x2013;<lpage>86</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2017/4156361</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ventura</surname> <given-names>RD</given-names>
</name>
<name>
<surname>Chaves</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Magalh&#xe3;es</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Gonzalez</surname> <given-names>FB</given-names>
</name>
<name>
<surname>Pacini</surname> <given-names>MF</given-names>
</name>
<name>
<surname>P&#xe9;rez</surname> <given-names>AR</given-names>
</name>
<etal/>
</person-group>. <article-title>Activation of PPAR&#x3b3; reduces N-acetyl-cysteine -induced hypercorticoidism by down-regulating MC2R expression into adrenal glands</article-title>. <source>Free Radic Biol Med</source>. (<year>2020</year>) <volume>156</volume>:<page-range>137&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.06.008</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lambrecht</surname> <given-names>RW</given-names>
</name>
<name>
<surname>Donohue</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Bonkovsky</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Shan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lambrecht</surname> <given-names>RW</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin</article-title>. <source>FASEB J</source>. (<year>2006</year>) <volume>20</volume>:<page-range>2651&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1096/fj.06-6346fje</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahuja</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ammal Kaidery</surname> <given-names>N</given-names>
</name>
<name>
<surname>Attucks</surname> <given-names>OC</given-names>
</name>
<name>
<surname>McDade</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hushpulian</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Gaisin</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Bach1 derepression is neuroprotective in a mouse model of Parkinson&#x2019;s disease</article-title>. <source>Proc Natl Acad Sci</source>. (<year>2021</year>) <volume>118</volume>:<fpage>187</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.2111643118</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muniroh</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gumay</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Indraswari</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Bahtiar</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hardian</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bakri</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Activation of MIP-2 and MCP-5 expression in methylmercury-exposed mice and their suppression by N-acetyl-L-cysteine</article-title>. <source>Neurotox Res</source>. (<year>2020</year>) <volume>37</volume>:<page-range>827&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12640-020-00174-4</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>N-acetyl L-cysteine protects against cadmium-induced neuronal apoptosis</article-title>. <source>Neuropathol Appl Neurobiol</source>. (<year>2014</year>) <volume>40</volume>:<page-range>759&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/nan.12103</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lins</surname> <given-names>TLBG</given-names>
</name>
<name>
<surname>Gouveia</surname> <given-names>BB</given-names>
</name>
<name>
<surname>Barberino</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Silva</surname> <given-names>RLS</given-names>
</name>
<name>
<surname>Monte</surname> <given-names>APO</given-names>
</name>
<name>
<surname>Pinto</surname> <given-names>JGC</given-names>
</name>
<etal/>
</person-group>. <article-title>Rutin prevents cisplatin-induced ovarian damage via antioxidant activity and regulation of PTEN and FOXO3a phosphorylation in mouse model</article-title>. <source>Reprod Toxicol</source>. (<year>2020</year>) <volume>98</volume>:<page-range>209&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.reprotox.2020.10.001</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Schmittgen</surname> <given-names>TD</given-names>
</name>
</person-group>. <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2&#x2013;&#x394;&#x394;CT method</article-title>. <source>Methods</source>. (<year>2001</year>) <volume>25</volume>:<page-range>402&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaves A da</surname> <given-names>S</given-names>
</name>
<name>
<surname>Magalh&#xe3;es</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Insuela</surname> <given-names>DBR</given-names>
</name>
<name>
<surname>Silva</surname> <given-names>PMRE</given-names>
</name>
<name>
<surname>Martins</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>VF</given-names>
</name>
</person-group>. <article-title>Effect of the renin-angiotensin system on the exacerbation of adrenal glucocorticoid steroidogenesis in diabetic mice: Role of angiotensin-II type 2 receptor</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1040040</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/FENDO.2022.1040040</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conti</surname> <given-names>V</given-names>
</name>
<name>
<surname>Izzo</surname> <given-names>V</given-names>
</name>
<name>
<surname>Corbi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Russomanno</surname> <given-names>G</given-names>
</name>
<name>
<surname>Manzo</surname> <given-names>V</given-names>
</name>
<name>
<surname>De Lise</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Antioxidant supplementation in the treatment of aging-associated diseases</article-title>. <source>Front Pharmacol</source>. (<year>2016</year>) <volume>7</volume>:<elocation-id>24</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2016.00024</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myung</surname> <given-names>S-K</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>HJ</given-names>
</name>
</person-group>. <article-title>Efficacy of vitamin and antioxidant supplements in prevention of esophageal cancer: meta-analysis of randomized controlled trials</article-title>. <source>J Cancer Prev</source>. (<year>2013</year>) <volume>18</volume>:<page-range>135&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.15430/JCP.2013.18.2.135</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Bjelakovic</surname> <given-names>G</given-names>
</name>
<name>
<surname>Nikolova</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gluud</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Simonetti</surname> <given-names>RG</given-names>
</name>
<name>
<surname>Gluud</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Bjelakovic</surname> <given-names>G</given-names>
</name>
</person-group>, editor. <source>Cochrane Database of Systematic Reviews</source>. <publisher-name>John Wiley &amp; Sons, Ltd</publisher-name>, <publisher-loc>Chichester, UK</publisher-loc> (<year>2008</year>). doi:&#xa0;<pub-id pub-id-type="doi">10.1002/14651858.CD007176</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macpherson</surname> <given-names>H</given-names>
</name>
<name>
<surname>Pipingas</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pase</surname> <given-names>MP</given-names>
</name>
</person-group>. <article-title>Multivitamin-multimineral supplementation and mortality: a meta-analysis of randomized controlled trials</article-title>. <source>Am J Clin Nutr</source>. (<year>2013</year>) <volume>97</volume>:<page-range>437&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3945/ajcn.112.049304</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Lawrenson</surname> <given-names>JG</given-names>
</name>
</person-group>. <article-title>Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration</article-title>. <source>Cochrane Database Systematic Rev</source>. (<year>2017</year>) <volume>2017</volume>:<fpage>600</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/14651858.CD000254.pub4</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname> <given-names>T-H</given-names>
</name>
<name>
<surname>Shieh</surname> <given-names>J-M</given-names>
</name>
<name>
<surname>Tsou</surname> <given-names>C-J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>W-B</given-names>
</name>
</person-group>. <article-title>Gold nanoparticles induce heme oxygenase-1 expression through Nrf2 activation and Bach1 export in human vascular endothelial cells</article-title>. <source>Int J Nanomed</source>. (<year>2015</year>) <volume>10</volume>:<page-range>5925&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/IJN.S88514</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>G</given-names>
</name>
<name>
<surname>Vaughn</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>ET</given-names>
</name>
<name>
<surname>Garcia-Cardena</surname> <given-names>G</given-names>
</name>
<name>
<surname>Gimbrone</surname> <given-names>MA</given-names>
</name>
</person-group>. <article-title>Biomechanical forces in atherosclerosis-resistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/Akt-dependent activation of Nrf2</article-title>. <source>Circ Res</source>. (<year>2007</year>) <volume>101</volume>:<page-range>723&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.152942</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horie</surname> <given-names>M</given-names>
</name>
<name>
<surname>Warabi</surname> <given-names>E</given-names>
</name>
<name>
<surname>Komine</surname> <given-names>S</given-names>
</name>
<name>
<surname>Oh</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shoda</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Cytoprotective role of nrf2 in electrical pulse stimulated C2C12 myotube</article-title>. <source>PloS One</source>. (<year>2015</year>) <volume>10</volume>:<fpage>e0144835</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0144835</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kheir-Eldin</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Motawi</surname> <given-names>TK</given-names>
</name>
<name>
<surname>Gad</surname> <given-names>MZ</given-names>
</name>
<name>
<surname>Abd-ElGawad</surname> <given-names>HM</given-names>
</name>
</person-group>. <article-title>Protective effect of vitamin E, &#x3b2;-carotene and N-acetylcysteine from the brain oxidative stress induced in rats by lipopolysaccharide</article-title>. <source>Int J Biochem Cell Biol</source>. (<year>2001</year>) <volume>33</volume>:<page-range>475&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1357-2725(01)00032-2</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Repetto</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Wiszniewski</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bonelli</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Vecino</surname> <given-names>CV</given-names>
</name>
<name>
<surname>Martinez Calejman</surname> <given-names>C</given-names>
</name>
<name>
<surname>Arias</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Impaired HPA axis function in diabetes involves adrenal apoptosis and phagocytosis</article-title>. <source>Endocrine</source>. (<year>2019</year>) <volume>63</volume>:<page-range>602&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12020-018-1755-5</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Astort</surname> <given-names>F</given-names>
</name>
<name>
<surname>Repetto</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Calejman</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Cipelli</surname> <given-names>JM</given-names>
</name>
<name>
<surname>S&#xe1;nchez</surname> <given-names>R</given-names>
</name>
<name>
<surname>Di Gruccio</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>High glucose-induced changes in steroid production in adrenal cells</article-title>. <source>Diabetes Metab Res Rev</source>. (<year>2009</year>) <volume>25</volume>:<page-range>477&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/dmrr.978</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keller-Wood</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Hypothalamic-pituitary-adrenal axis&#x2014;Feedback control</article-title>. <source>Compr Physiol Wiley</source>. (<year>2015</year>) <volume>p</volume>:<page-range>1161&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cphy.c140065</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname> <given-names>JP</given-names>
</name>
<name>
<surname>McKlveen</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Ghosal</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kopp</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wulsin</surname> <given-names>A</given-names>
</name>
<name>
<surname>Makinson</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of the hypothalamic-pituitary-adrenocortical stress response</article-title>. <source>Compr Physiol Wiley</source>. (<year>2016</year>) <volume>p</volume>:<page-range>603&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cphy.c150015</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korou</surname> <given-names>L-M</given-names>
</name>
<name>
<surname>Agrogiannis</surname> <given-names>G</given-names>
</name>
<name>
<surname>Koros</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kitraki</surname> <given-names>E</given-names>
</name>
<name>
<surname>Vlachos</surname> <given-names>IS</given-names>
</name>
<name>
<surname>Tzanetakou</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of N-acetylcysteine and sesame oil on lipid metabolism and hypothalamic-pituitary-adrenal axis homeostasis in middle-aged hypercholesterolemic mice</article-title>. <source>Sci Rep</source>. (<year>2014</year>) <volume>4</volume>:<elocation-id>6806</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep06806</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramos-Ram&#xed;rez</surname> <given-names>P</given-names>
</name>
<name>
<surname>Tliba</surname> <given-names>O</given-names>
</name>
</person-group>. <article-title>Glucocorticoid receptor &#x3b2; (GR&#x3b2;): beyond its dominant-negative function</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<elocation-id>3649</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms22073649</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kino</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tiulpakov</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ichijo</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chheng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kozasa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chrousos</surname> <given-names>GP</given-names>
</name>
</person-group>. <article-title>G protein &#x3b2; interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus</article-title>. <source>J Cell Biol</source>. (<year>2005</year>) <volume>169</volume>:<page-range>885&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1083/jcb.200409150</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lockett</surname> <given-names>J</given-names>
</name>
<name>
<surname>Inder</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Clifton</surname> <given-names>VL</given-names>
</name>
</person-group>. <article-title>The glucocorticoid receptor: isoforms, functions, and contribution to glucocorticoid sensitivity</article-title>. <source>Endocr Rev</source>. (<year>2024</year>) <volume>45</volume>:<fpage>593</fpage>&#x2013;<lpage>624</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/endrev/bnae008</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otto</surname> <given-names>C</given-names>
</name>
<name>
<surname>Reichardt</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Sch&#xfc;tz</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Absence of glucocorticoid receptor-&#x3b2; in mice</article-title>. <source>J Biol Chem</source>. (<year>1997</year>) <volume>272</volume>:<page-range>26665&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.272.42.26665</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname> <given-names>GC</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Millar</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Clark</surname> <given-names>AF</given-names>
</name>
</person-group>. <article-title>Glucocorticoid receptor GR&#x3b2; regulates glucocorticoid-induced ocular hypertension in mice</article-title>. <source>Sci Rep</source>. (<year>2018</year>) <volume>8</volume>:<fpage>862</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-018-19262-9</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinds</surname> <given-names>TD</given-names>
</name>
<name>
<surname>Ramakrishnan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cash</surname> <given-names>HA</given-names>
</name>
<name>
<surname>Stechschulte</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Heinrich</surname> <given-names>G</given-names>
</name>
<name>
<surname>Najjar</surname> <given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Discovery of glucocorticoid receptor-&#x3b2; in mice with a role in metabolism</article-title>. <source>Mol Endocrinol</source>. (<year>2010</year>) <volume>24</volume>:<page-range>1715&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/me.2009-0411</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname> <given-names>A</given-names>
</name>
<name>
<surname>Marandici</surname> <given-names>A</given-names>
</name>
<name>
<surname>Monder</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Metabolism of corticosterone in the mouse. Identification of 11 beta, 20 alpha-dihydroxy-3-oxo-4-pregnen-21-oic acid as a major metabolite</article-title>. <source>J Biol Chem</source>. (<year>1983</year>) <volume>258</volume>:<page-range>13703&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0021-9258(17)43974-3</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foresti</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bains</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Pitchumony</surname> <given-names>TS</given-names>
</name>
<name>
<surname>de Castro Br&#xe1;s</surname> <given-names>LE</given-names>
</name>
<name>
<surname>Drago</surname> <given-names>F</given-names>
</name>
<name>
<surname>Dubois-Rand&#xe9;</surname> <given-names>J-L</given-names>
</name>
<etal/>
</person-group>. <article-title>Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells</article-title>. <source>Pharmacol Res</source>. (<year>2013</year>) <volume>76</volume>:<page-range>132&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phrs.2013.07.010</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ndisang</surname> <given-names>JF</given-names>
</name>
</person-group>. <article-title>Synergistic interaction between heme oxygenase (HO) and nuclear-factor E2- related factor-2 (Nrf2) against oxidative stress in cardiovascular related diseases</article-title>. <source>Curr Pharm Des</source>. (<year>2017</year>) <volume>23</volume>:<page-range>1465&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1381612823666170113153818</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>R</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress</article-title>. <source>J Adv Res</source>. (<year>2021</year>) <volume>34</volume>:<fpage>43</fpage>&#x2013;<lpage>63</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jare.2021.06.023</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>